Relmada Therapeutics (RLMD): Price/Earnings to Growth Ratio
Relmada Therapeutics (RLMD) develops innovative depression therapies through NMDA receptor modulation using the drug REL-1017. The PEG ratio history demonstrates valuation dynamics, where the 0.00 indicator determines the metric's magnitude. The operating model is based on the full outsourcing of production and clinical trials. However, the business relies on speculative esomethadone patents, and success depends on the results of future trials.
Analytical breakdowns for Relmada Therapeutics (RLMD)
- current quotes and average value forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Relmada Therapeutics|RLMD - Long-Term Debt to Capital|Short-Term Debt to Capital relmada.com|RLMD - Company Total Debt|Debt to Net Assets Ratio Relmada|RLMD - Company Long-Term Liabilities|Amount of Current Liabilities Relmada Therapeutics|Intermediate Coverage Ratio relmada.com
- business earnings and investment ratios data:
RLMD - Net Profit|Expected Net Profit Relmada Therapeutics|RLMD - Price to Earnings Ratio|Future Price to Earnings Multiple Relmada Corp|RLMD - PEG Multiple|EV/EBITDA Multiple Relmada|RLMD - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Relmada Therapeutics|RLMD - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months relmada.com|RLMD - Net earnings per share growth this year|Earnings growth forecast for next year Relmada Therapeutics
Summary company analytics:Relmada Therapeutics Inc, RLMD
Fundamental risks for Relmada Therapeutics (RLMD) require a comparison of the share price with earnings dynamics. For a biotech startup awaiting the commercialization of the drug REL-1017, assessing expansion rates is critical. The current PEG value on the GURU.Markets platform reflects the ratio of the P/E coefficient to the annual growth of net income. A value below one signals that the asset is undervalued relative to its potential. Analysis of the chart allows for a determination of whether the market is adequately pricing management efficiency.
Who Relmada Therapeutics competes with
BIIB - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|Regencell Corp - Price/Earnings to Growth Ratio|AXSM - Price/Earnings to Growth Ratio|acadia-pharm.com (ACAD) - Price/Earnings to Growth Multiple|XENE: PEG Multiple|Viking Therapeutics Inc (VKTX) - PEG Multiple|SUPN (Supernus Pharma) - PEG Multiple|Growth-Adjusted P/E Ratio CPRX (Catalyst Corp)|PEG Multiple DNLI|PEG Multiple harmonybiosciences.com (HRMY)|Biohaven - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio AMLX|TRVI: Price/Earnings to Growth Multiple|Praxis Corp - Company Value to Earnings Growth Ratio|AVXL: PEG Multiple|ceribell.com - Growth-Adjusted Payback Ratio|PRTA (Prothena Corporation plc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Alector Therapeutics ALEC|Price/Earnings to Growth Ratio Annexon Inc. (ANNX)|OMER (omeros.com) - Growth-Adjusted Payback Ratio|PEG Multiple NGNE (Neurogene Inc.)|PEG Multiple acimmune.com ACIU|VYGR - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NMRA|SCLX: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tevogen Bio Inc. (TVGN)|Price/Earnings to Growth Multiple ACOG|PEG Multiple cogrx.com|Price/Earnings to Growth Multiple IKT (Inhibikase Therapeutics, Inc.)|Company Value to Earnings Growth Ratio SAVA|PEG Multiple ASRT (Assertio)|Growth-Adjusted Market Cap to Net Income Coya Therapeutics Inc (COYA)|VistaGen Therapeutics Inc - PEG Multiple|Ovid Therapeutics Inc. (OVID) - Price/Earnings to Growth Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Price/Earnings to Growth Ratio|CRVO - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Alterity Therapeutics Ltd.|CLNN: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio PepGen Inc. (PEPG)|Price/Earnings to Growth Ratio JUNS (jupiterneurosciences.com)|Price/Earnings to Growth Ratio Annovis Bio ANVS|GRCE - Price/Earnings to Growth Multiple|Firefly Neuroscience Inc - PEG Multiple|KLTO (Klotho Neurosciences Inc) - Growth-Adjusted P/E Ratio|neurosense-tx.com (NRSN) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio RVPH|MTVA (MetaVia Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NeurAxis Inc. NRXS|Price/Earnings to Growth Multiple HSDT (Helius Medical)|PEG Multiple passagebio.com (PASG)|Price/Earnings to Growth Ratio Neuphoria Therapeutics NEUP|Growth-Adjusted Payback Ratio NERV|ATHA - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Addex Therapeutics Ltd.|alzamend.com (ALZN) - Price/Earnings to Growth Ratio|Cyclerion Therapeutics, Inc. - Growth-Adjusted Payback Ratio|PTIX (Protagenic Therapeutics Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Pasithea KTTA|Price/Earnings to Growth Ratio Cortigent, Inc. (CRGT)|Price/Earnings to Growth Ratio ATXI (Avenue Therapeutics Inc.)|Price/Earnings to Growth Ratio Brainstorm Cell Therapeutics, Inc. BCLI|CARA - Price/Earnings to Growth Multiple|Chromocell Therapeutics - PEG Multiple|ELYM - PEG Multiple|ITCI: PEG Multiple|Growth-Adjusted P/E Ratio LBPH|MRNS (Marinus) - PEG Multiple|PEG Multiple NKGen Biotech Corp|Price/Earnings to Growth Multiple NRBO (NeuroBo Pharmaceuticals)|SAGE (sagerx.com) - Growth-Adjusted Payback Ratio|Synaptogenix - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio TRVN (Trevena Inc.)|Vigil Neuro - PEG Multiple|Growth-Adjusted Payback Ratio WENA (Anew Medical Inc.)|CERE: PEG Multiple
